August 7, 2020

The Niche

Knoepfler lab stem cell blog

Mesenchymal stem cells (MSCs)

5 min read

Ready for the latest recommended weekly reads in the world of stem cells and the regenerative medicine space including a bunch of important new FDA posts & changes? This post has quite a lot on the FDA since it had a very big week with several new items of major importance to the cellular and regenerative medicine arena. I’ve linked to each announcement below with the agency’s title of the announcements. Underneath I provide some analysis and ask questions. I’ve also included some other stem …Read More

5 min read

The biotech Mesoblast is starting an expanded access study of its stem cell product for kids with a severe offshoot of COVID-19. The cellular drug in this case is remestemcel-L (more below). While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe disease than the average COVID patient and some die. Physicians need more potential treatment options here for these children. In that sense one could argue that testing more new …Read More

6 min read

Advanced Cell Technology (ACT; $ACTC) has a new paper out on using human embryonic stem cells (hESC) to make MSCs with potentially powerful therapeutic potential. The paper, entitled Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties, was published in the journal Stem Cells and Development. What’s the scoop on this paper and this area of adult stem cell preclinical/clinical research? It’s an interesting, notable paper. At the same time there are some areas in the paper that could have been …Read More

3 min read

Is Advanced Cell Technology (ACT) on the road to cure Multiple Sclerosis (MS) using stem cells and specifically MSCs? Some folks seem to think it’s quite possible, but I remain skeptical. Still there have been some interesting developments. ACT has a relatively new patent filing for a mesenchymal stromal cell (MSC) product that was just recently published. The filing has 125 claims. Wow. Mentioned prominently in the patent filing is MS as a target disease. In fact, there are rumors that ACT has already …Read More